Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
Dollar change
Percentage change
CategoryTarget Date / Multi-Asset - Other Asset TypeMulti-Asset - Tactical / Active TagsU.S. Return% 1Y25.24% Shs Outstand Perf Week10.83%
SponsorSimplify ETF ETF Type Tagsequity Return% 3Y- Total Holdings25 Perf Month1.44%
Fund Family Bond Type Tagsbonds Return% 5Y- AUM104.94M Perf Quarter1.64%
Index- Average Maturity Tagsmulti-asset Return% 10Y NAV% Perf Half Y15.02%
Index Weighting Commodity Type Tagshealthcare Return% SI NAV/sh Perf Year10.39%
Active/Passive Quant Type Tagsbiotechnology Flows% 1M0.21% 52W Range17.93 - 26.78 Perf YTD15.93%
Dividend TTM3.29 (13.73%) ESG Type Tagspharmaceutical Flows% 3M1.29% 52W High-10.54% Beta1.40
Dividend Ex-DateJun 25, 2024 Dividend Type Sector/Theme Flows% YTD-1.92% 52W Low33.65% ATR (14)0.47
Expense2.51% Structure Type Region Flows% 1Y RSI (14)63.85 Volatility0.28% 1.13%
Option/ShortNo / Yes Growth/Value Dev/Emerg Flows% 3Y Rel Volume0.26 Prev Close23.75
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume2.72K Price23.96
SMA206.07% SMA505.84% SMA20010.03% Trades Volume703 Change0.90%
Simplify Propel Opportunities ETF seeks to provide long-term growth of capital. The fund is an actively managed exchange-traded fund. The Sub-Adviser concentrates the fund's investments (i.e., invests more than 25% of its net assets) in the securities of issuers in the biotechnology, pharmaceuticals, healthcare technology, and life science tools and services industries. The Sub-Adviser employs an actively managed opportunistic multi-asset strategy that focuses on common stock, preferred stock, convertible bonds, structured notes, corporate notes and bonds, and ETFs that primarily invest in the preceding security types. The fund is non-diversified.